95 related articles for article (PubMed ID: 2432985)
1. Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex).
Siddall JK; Hetherington JW; Cooper EH; Newling DW; Robinson MR; Richards B; Denis L
Br J Urol; 1986 Dec; 58(6):676-82. PubMed ID: 2432985
[TBL] [Abstract][Full Text] [Related]
2. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
[TBL] [Abstract][Full Text] [Related]
3. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Schulze H; Senge T
J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
[TBL] [Abstract][Full Text] [Related]
4. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
5. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
6. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
Ahmed SR; Grant JB; Shalet SM; Howell A; Costello CB; Weatherson T; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):534-8. PubMed ID: 2946355
[TBL] [Abstract][Full Text] [Related]
7. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
8. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
9. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
10. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
[TBL] [Abstract][Full Text] [Related]
11. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
[TBL] [Abstract][Full Text] [Related]
12. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M
Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
[TBL] [Abstract][Full Text] [Related]
13. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
Mahler C; Verhelst J; Chaban M; Denis L
Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
[TBL] [Abstract][Full Text] [Related]
14. Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate.
Sasagawa I; Kubota Y; Nakada T; Suzuki H; Hirano J; Sugano O; Kato H; Imamura A; Mastushita K; Onmura Y; Saito M; Adachi M
Int Urol Nephrol; 1998; 30(6):745-53. PubMed ID: 10195870
[TBL] [Abstract][Full Text] [Related]
15. Results obtained in the treatment of prostate cancer patients with Zoladex.
Williams G; Kerle DJ; Roe SM; Yeo T; Bloom SR
Prog Clin Biol Res; 1985; 185A():287-95. PubMed ID: 3162175
[No Abstract] [Full Text] [Related]
16. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
Metz R; Namer M; Adenis L; Audhuy B; Bugat R; Colombel P; Couette JE; Grise P; Khater R; LePorz B
Am J Clin Oncol; 1988; 11 Suppl 2():S112-4. PubMed ID: 2977263
[TBL] [Abstract][Full Text] [Related]
17. Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.
Johansen TE; Ogreid P; Kjellevold K; Blom P
Br J Urol; 1990 Apr; 65(4):376-8. PubMed ID: 2140282
[TBL] [Abstract][Full Text] [Related]
18. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
[TBL] [Abstract][Full Text] [Related]
19. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
[TBL] [Abstract][Full Text] [Related]
20. Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
Mauriac L; Coste P; Richaud P; Lamarche P; Mage P; Bonichon F
Am J Clin Oncol; 1988; 11 Suppl 2():S117-9. PubMed ID: 2977265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
